Citrate Pharmacokinetics in Critically Ill Liver Failure Patients Receiving CRRT (Citrate PK)

Chulalongkorn University

Status: Completed

Conditions: Pharmacokinetic; Regional Citrate Anticoagulation; Continuous Renal Replacement Therapy; Citrate Toxicity; Liver Failure, Acute on Chronic; Liver Failure, Acute

Treatments: Diagnostic Test: Pharmacokinetic study

Study type: Interventional

Funder types: Other

Identifiers

NCT04959110

IRB.694/63

Details and patient eligibility

About

Citrate has been proposed as anticoagulation of choice in continuous renal replacement therapy (CRRT). However, little is known about the pharmacokinetics (PKs) and metabolism of citrate in liver failure patients who require CRRT with regional citrate anticoagulation (RCA).

Full description

This study aimed to evaluate citrate PKs, metabolic complications, and clinical outcomes among critically ill acute liver failure (ALF) and acute on top chronic liver failure (ACLF) patients receiving CRRT.

Enrollment: 20 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Critically ill ALF or ACLF adult patients with AKI
• aged ≥ 18 y old
• Currently receiving CRRT.

Exclusion criteria

• severe acidosis (pH < 7.1) or severe alkalosis (pH > 7.55)
• blood transfusion within 24 h prior to the study
• use of citrate-containing medications
• severe hypocalcemia (serum ionized calcium < 0.8 mmol/L)
• use of heparin as anticoagulation

Trial design

Primary purpose: Diagnostic

Allocation: Non-Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

20 participants in 2 patient groups

Acute Liver Failure

Experimental group

Description:

Acute liver failure critically ill patients receiving CRRT

Treatment:

Diagnostic Test: Pharmacokinetic study

Acute on top Chronic Liver Failure

Experimental group

Description:

Acute on top chronic liver failure critically ill patients receiving CRRT

Treatment:

Diagnostic Test: Pharmacokinetic study